Natasha Dalton
Family · Christiansburg, VANPI 1912471020
Payments from drug & device makers
Across 229 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$904
- Sanofi$512
- Pharming Healthcare, Inc.$291
- Takeda Pharmaceuticals U.S.A., Inc.$228
- Amgen$218
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,28291%
- Education$3999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 57 | $1,244 |
| AstraZeneca | 45 | $904 |
| Sanofi | 28 | $512 |
| Pharming Healthcare, Inc. | 11 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $228 |
| Amgen(2 entities) | 12 | $218 |
| GSK | 13 | $214 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $197 |
| CSL Behring | 8 | $172 |
| Genentech USA, Inc. | 6 | $136 |
| Novartis | 5 | $125 |
| Optinose US, Inc. | 6 | $117 |
| Biocryst US Sales Co., LLC | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| AbbVie | 2 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $24 |
| Pfizer | 1 | $21 |
| Merck | 1 | $17 |
| Nevro Corp. | 1 | $15 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$120
How this compares
$4,681 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,553 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,769 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,280 |
| Epinephrine | 13 | $2,765 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $859 |
| Azelastine Hcl | 16 | $762 |
| Montelukast Sodium | 44 | $719 |
| Levocetirizine Dihydrochloride | 16 | $317 |
| Ipratropium Bromide | 12 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $214 | $17,55320 claims |
| AstraZenecaSymbicort | $904 | $4,28014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Christiansburg
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.